FDA approves sotorasib with panitumumab for colorectal cancer
2 days ago · On Jan. 15, 2025, the FDA approved sotorasib (Lumakras, Amgen Inc.) with panitumumab (Vectibix, Amgen Inc.) for KRAS G12C-mutated metastatic colorectal cancer.
FDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION …
1 day ago · The CodeBreaK 300 trial enrolled 160 participants and compared LUMAKRAS ® (sotorasib) at doses of 960 mg and 240 mg in combination with Vectibix ® (panitumumab) to investigator's choice of standard of care (trifluridine/tipiracil or regorafenib) in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC). The study ...
FDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION …
1 day ago · The CodeBreaK 300 trial enrolled 160 participants and compared LUMAKRAS ® (sotorasib) at doses of 960 mg and 240 mg in combination with Vectibix ® (panitumumab) to investigator’s choice of standard of care (trifluridine/tipiracil or regorafenib) in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC). The ...
Sotorasib plus Panitumumab in Refractory Colorectal Cancer …
Oct 22, 2023 · In this phase 3 trial of a KRAS G12C inhibitor plus an EGFR inhibitor in patients with chemorefractory metastatic colorectal cancer, 960-mg sotorasib in combination with panitumumab resulted in...
Sotorasib for previously treated colorectal cancers with
Dec 14, 2021 · Sotorasib, a specific, irreversible KRASG12C protein inhibitor, has shown monotherapy clinical activity in KRASG12C -mutated solid tumours, including colorectal cancer, in the CodeBreaK100 phase 1 trial. We aimed to investigate the activity and safety of sotorasib in phase 2 of the trial.
A phase 1b study of sotorasib combined with panitumumab as …
Jan 22, 2024 · Background: In the CodeBreaK 101 phase 1b study, sotorasib, a KRAS G12C inhibitor, plus panitumumab, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody, showed acceptable safety and promising efficacy for patients with chemorefractory KRAS G12C–mutated metastatic colorectal cancer: …
Sotorasib plus Panitumumab in Refractory Colorectal Cancer
Oct 23, 2023 · In this phase 3 trial of a KRAS G12C inhibitor plus an EGFR inhibitor in patients with chemorefractory metastatic colorectal cancer, both doses of sotorasib in combination with panitumumab resulted in longer progression-free survival than standard treatment.
Combining the KRAS G12C inhibitor sotorasib with the epidermal growth factor receptor (EGFR) inhibitor panitumumab showed promise in an early trial involving patients with chemorefractory...
LBA10 Sotorasib plus panitumumab versus standard-of-care for ...
We report the first Phase 3 primary results for sotorasib (soto), a KRAS G12C -inhibitor, plus panitumumab (pani), an anti-EGFR antibody, vs standard of care (SOC) in patients (pts) with chemorefractory KRAS G12C-mutated mCRC.
Sotorasib with panitumumab in chemotherapy-refractory - Nature
Jan 4, 2024 · This phase 1b, multicenter, open-label study of sotorasib plus panitumumab in adult patients with KRAS G12C-mutated advanced colorectal cancer included a dose-exploration cohort and a dose ...
- Some results have been removed